Helmholtz Alliance ICEMED
Imaging and Curing Environmental Metabolic Diseases
The Helmholtz Alliance ICEMED is a network of complementary research excellence representing a worldwide unique research consortium of biomedical research scientists, clinicians and cutting edge metabolic imaging experts in Germany. ICEMED consists of more than 30 leading German diabetes and obesity research teams and research centers enhanced by cooperative alliances with Sanofi Aventis Pharmaceuticals and leading international diabetes and obesity research centers at Cambridge and Yale University. The overarching intent of this alliance is to embrace the sustainable theme of finding new medicines to prevent and cure obesity and type 2 Diabetes over the next five years. The alliance will focus on identifying, visualizing, dissecting and targeting neural pathways (in both central control circuits and brain-periphery crosstalk) that regulate systems metabolism. This aspect of the alliance is synergistically enhanced by the integration of comprehensive neuroimaging expertise using cutting edge, in vivo metabolic imaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) in animal models and humans. ICEMED connects multi-disciplinary basic research with clinical application toward personalized medicine.
The alliance is headed by the principal coordinators Prof Matthias Tschöp (Munich), Prof Mathias Treier (MDC Berlin) and Prof Jon Shah (Jülich).
For more information please visit the project website.